Science Current Events | Science News |

Three studies point to effectiveness of new therapies for multiple myeloma

December 08, 2015

ORLANDO, FL -- In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana-Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment-resistant forms of the disease.

The trials pair the oral drugs lenalidomide and dexamethasone with other agents, each of which exploits a different vulnerability in tumor cells. The various combinations are at different stages of clinical testing, but all are proving effective at producing at least partial remissions and increasing the duration of those remissions, with tolerable side effects for most patients.

"With the recent approvals of daratumumab, ixazomib, and now elotuzumab, we have seen an unprecedented pace of progress in myeloma therapy this year. The results from these studies reflect the real benefits our patients can anticipate from these very important advances in currently available treatment," said Paul Richardson, clinical program leader and director of clinical research at Dana-Farber's Jerome Lipper Multiple Myeloma Center.

All of the patients in the three trials had myeloma that had either relapsed or become resistant to other therapies. Patients received a tandem of lenalidomide, a drug that kills tumor cells, blocks blood vessel growth, and acts on the immune system, and dexamethasone, an anti-inflammatory agent, plus one of three new agents:

A combined phase 1 and phase 2 trial of lenalidomide/dexamethasone plus a breakthrough antibody therapy called daratumumab (Darzalexâ„¢). Of 32 patients participating in the trial, 11 had a partial response to the drug regimen, meaning a decrease in the extent of the cancer, and 53 had a very good partial response, meaning the level of certain myeloma-related proteins in the blood declines by more than 90 percent. In 93 percent of cases, remissions lasted for the entire 12 months that the patients have been tracked so far. The most common adverse side effects were neutropenia (a shortage of certain white blood cells), muscle spasms, cough, diarrhea, fatigue, and hypertension.

Abstract # 507 embargoed until presented Monday, December 7, at 7:30 a.m. ET, in Hall E1, Level 2, Orange County Convention Center

A phase 3 trial of lenalidomide/dexamethasone plus ixazomib (Ninlaro®), a 'proteasome inhibitor' that blocks the ability of cancer cells to reuse certain proteins. The U.S. Food and Drug Administration approved the drug on Nov. 20 for patients with myeloma who have received at least one previous therapy. In the trial, patients receiving all three drugs had a 35 percent improvement in progression-free survival -- the length of time before the disease begins to worsen -- compared to those receiving lenalidomide and dexamethasone alone. The adverse side effects were similar in intensity and prevalence to those associated with lenalidome and dexamethasone.

Abstract # 727 embargoed until presented Monday, December 7, at 2:45 p.m. ET, in Tangerine 2 (WF2), Level 2 of the Orange County Convention Center

A phase 3 trial of lenalidomide/dexamethasone with elotuzumab (Emplicitiâ„¢), an antibody therapy that attacks myeloma cells directly and spurs the immune system to launch an attack of its own. Treatment with the three-drug regimen resulted in a 30 percent reduction in the risk that the disease would progress over a three-year period, compared to a course of lenalidomide and dexamethasone alone. Overall, 79 percent of the 321 patients who received the three-drug regimen responded to it, compared to 66 percent of the 325 patients in the two-drug group. The most common adverse side effects were lymphopenia (a condition of abnormally low levels of white blood cells called lymphocytes), neutropenia, blood platelet deficiency, and infection.

Abstract #28 embargoed until presented Saturday, December 5, at 8:15 AM, on Tangerine 2 (WF2), Level 2 of the Orange County Convention Center

"In summary, these encouraging data build upon the real success of our translational efforts in myeloma over the last decade, and provide exciting new options with the real promise of improving patient outcome," said Richardson, who is also the R.J. Corman professor at Harvard Medical School.

For a full list of co-authors and their affiliated institutions for each of the abstracts, please visit


About Dana-Farber Cancer Institute

From achieving the first remissions in cancer with chemotherapy in 1948, to developing the very latest new therapies, Dana-Farber Cancer Institute is one of the world's leading centers of cancer research and treatment. It is the only center ranked in the top 4 of U.S. News and World Report's Best Hospitals for both adult and pediatric cancer care.

Dana-Farber sits at the center of a wide range of collaborative efforts to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber/Brigham and Women's Cancer Center provides the latest in cancer care for adults; Dana-Farber/Boston Children's Cancer and Blood Disorders Center for children. The Dana-Farber/Harvard Cancer Center unites the cancer research efforts of five Harvard academic medical centers and two graduate schools, while Dana-Farber Community Cancer Care provides high quality cancer treatment in communities outside Boston's Longwood Medical Area.

Dana-Farber is dedicated to a unique 50/50 balance between cancer research and care, and much of the Institute's work is dedicated to translating the results of its discovery into new treatments for patients in Boston, and around the world.

Dana-Farber Cancer Institute

Related Dexamethasone Current Events and Dexamethasone News Articles

Nanoscale Trojan horses treat inflammation
Nanosized Trojan horses created from a patient's own immune cells have successfully treated inflammation by overcoming the body's complex defense mechanisms, perhaps leading to broader applications for treating diseases characterized by inflammation, such as cancer and cardiovascular diseases.

Updated Cochrane Review: Corticosteroids for managing tuberculous meningitis
The Cochrane Infectious Diseases Group (CIDG) have carried out a review update to evaluate the effects of corticosteroids being used alongside anti-tuberculosis medication to treat people suffering from tuberculous meningitis.

Preliminary study: Antibody therapy reduces cancer stem cells in multiple myeloma
An experimental antibody treatment decreased by half the number of cancer stem cells that drive the growth of tumors in nearly all patients with multiple myeloma, a cancer of the bone marrow and bone tissue, according to results of a preliminary clinical trial led by Johns Hopkins Kimmel Cancer Center scientists.

Netupitant/palonosetron for prevention of nausea and vomiting: Added benefit not proven
The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether the drug combination netupitant/palonosetron (trade name: Akynzeo) offers an added benefit over the appropriate comparator therapy (ACT).

D&R: A new adipogenic cocktail that produces functional adipocytes from MSCs
Adipocyte dysfunction is directly associated with pathologies characterized by metabolic disorders including obesity, diabetes mellitus type II and metabolic syndrome. Adipogenesis is a complex process that has been extensively studied in different cell models.

Studies suggest new ways to inhibit oncogenes, enhance tumor-suppressor activity
Two new studies by cancer scientists at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggest new approaches for treating cancer by inhibiting overactive cancer-promoting genes and by enhancing the activity of sluggish tumor-suppressor genes. The findings were reported in the journals Nature Communications and Nature Genetics.

Nanowire implants offer remote-controlled drug delivery
A team of researchers has created a new implantable drug-delivery system using nanowires that can be wirelessly controlled.

Stress hormones could undermine breast cancer therapy
Recently, researchers have discovered that the hormone progesterone, an ingredient in contraceptives and menopausal hormone replacement therapies, might stimulate the growth of breast cancer cells that are resistant to anti-estrogen therapy and chemotherapy.

Some common anti-nausea medications used post-operatively could increase patients' arrhythmia risk
Certain commonly prescribed anti-nausea medications given to patients during or after an operation could increase their risk of developing an irregular heartbeat, new research has found.

Discovery could help reverse glucocorticoid resistance in some young leukemia patients
Researchers led by St. Jude Children's Research Hospital scientists have identified a mechanism that helps leukemia cells resist glucocorticoids, a finding that lays the foundation for more effective treatment of cancer and possibly a host of autoimmune diseases.
More Dexamethasone Current Events and Dexamethasone News Articles

Dexamethasone: Therapeutic Uses, Mechanism of Action and Potential Side Effects (Pharmacology - Research, Safety Testing and Regulation)

Dexamethasone: Therapeutic Uses, Mechanism of Action and Potential Side Effects (Pharmacology - Research, Safety Testing and Regulation)
by Alexandre Sauvage (Editor), Maxime Levy (Editor)

Dexamethasone in the transdifferentiation of pancreatic buds

Dexamethasone in the transdifferentiation of pancreatic buds
by Hadia Hosny (Author)

Transdifferentiation is defined as the direct conversion of one differentiated cell type into another. Usually transdifferentiation occurs in cells originating from adjacent cells in the developing embryo. Transdifferentiation can also be induced experimentally by overexpressing the expression of ‘master switch genes’ or a single transcription factor. It is important to study the transdifferentiation state as it will be very useful in designing potential methods for cell therapy.One example of transdifferentiation is provided by two endodermally-derived tissues, liver and pancreas .The liver and pancreas arise from the same region in the endoderm and their transdifferentiation phenomenon has been observed in some studies such as Rao and Reddy experiments. Recently, researchers have...

Dexamethasone-induced: Webster's Timeline History, 1960 - 2007

Dexamethasone-induced: Webster's Timeline History, 1960 - 2007
by Icon Group International (Author)

Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Dexamethasone-induced," including when used in literature (e.g. all authors that might have Dexamethasone-induced in their name). As such, this book represents the largest compilation of timeline events associated with Dexamethasone-induced when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop...

Dexamethasone Iontophoresis in Treatment of Epicondilitis

Dexamethasone Iontophoresis in Treatment of Epicondilitis
by Ahmed Ibrahim Hammad (Author), Fatma Kamel (Editor), Eman Kaddah (Editor)

Pain is a red flag that mostly denotes a real problem. Joint pain alters its function. Many people complain of elbow pain that interfere with their daily activities. Right diagnosis is a must, by taking history, performing examination and investigations such as musculoskeletal sonography. Treatment of epicondylitis may be conservative, minimal invasive or surgical. Local injection or surgery are not preferable but may be the last option if other treatments do not resolve the problem. Iontophoresis appeared as the gate that allows drug entry in the needed dose without use of a needle and give good results.

Quality of Life After Third Molar Surgery: The effects and benefits of dexamethasone

Quality of Life After Third Molar Surgery: The effects and benefits of dexamethasone
by Oluwafemi Hassan (Author)

Following third molar surgery, the patients were mentally prepared to expect only pain and swelling; rather, they reported severe difficulty with eating/ mastication and lack of enjoyment of food, speech disturbances and lack of sleep. Work and duty, they complained were adversely affected; infact they could not socialize for more than one week, hence there quality of life were severely impacted. This showed a gap between the patients' expectations and their actual experience during the recovery period. Subjects who had perioperative dexamethasone administration, however had a rather different experience.

Brachial Plexus Block and Adjuvants: Tramadol VS Dexamethasone

Brachial Plexus Block and Adjuvants: Tramadol VS Dexamethasone
by Naimul Hoq (Author), Abdullah Al Maruf (Author), Sabrina Yesmin (Author)

Brachial plexus block is a suitable alternative to GA. It is reliable, safe, effective, low-cost and most complete anaesthesia with good postoperative analgesia for upper limb surgery. Local anaesthetics alone for supraclavicular brachial plexus block provide good operative conditions but have shorter duration of postoperative analgesia. Numerous adjuncts have been added to enhance the efficacy of the block. The work was undertaken to compare the onset time and duration of analgesia between tramadol and dexamethasone when used as an adjuvant to bupivacaine in supraclavicular brachial plexus block. Total 60 patients underwent upper extremity surgery under brachial plexus block were randomly divided into two equal groups of 30 each; one group received tramadol (2mg/kg) and the other group...

Dexamethasone for Prevention and Treatment of Acute Mountain Sickness

Dexamethasone for Prevention and Treatment of Acute Mountain Sickness
by Peter H. Hackett (Author)

Meyler's Side Effects of Endocrine and Metabolic Drugs (Meyler's Side Effects of Drugs)

Meyler's Side Effects of Endocrine and Metabolic Drugs (Meyler's Side Effects of Drugs)
by Jeffrey K. Aronson MA DPhil MBChB FRCP FBPharmacolS FFPM(Hon) (Author)

Elsevier now offers a series of derivative works based on the acclaimed Meylers Side Effect of Drugs, 15th Edition. These individual volumes are grouped by specialty to benefit the practicing physician or health care clinician. Endocrine and metabolic diseases are common, includes diseases such as diabetes, thyroid disease, and obesity. Endocrinologists, including diabetes professionals, internal medicine and primary care practitioners, obstetricians and gynecologists, and others will find this book useful when treating endocrine or metabolic diseases. The material is drawn from the 15th edition of the internationally renowned encyclopedia, Meyler’s Side Effects of Drugs, and the latest volumes in the companion series, Side Effects of Drugs Annuals. Drug names have usually been...

A  Simple  Guide  To  Hyper-cortisolism (Cushing Syndrome),  Diagnosis, Treatment  And  Related Conditions (A Simple Guide to Medical Conditions)

A Simple Guide To Hyper-cortisolism (Cushing Syndrome), Diagnosis, Treatment And Related Conditions (A Simple Guide to Medical Conditions)

Chapter 1

Hyper-cortisolism (Cushing’s Syndrome)

What is Hyper-cortosolism?

The exposure of the body to excess amounts of glucocorticoids steroids is the cause of the medical disorder Hyper-cortosolism (Cushing Syndrome).

The Hyper-cortosolism will happen when the body is exposed to high levels of the hormone cortisol and therefore the word Hyper-cortosolism is more appropriate than Cushing Syndrome.

It may also happen if the patient takes too much cortisol or other steroid hormones.

People of all ages are affected but more are seen in females from 30 to 50 years of age.

What are the causes of Hyper-cortosolism?

A. The most common cause of Hyper-cortosolism is taking excess...

Sulfure d'hydrogène, Protéine C activée et Dexaméthasone dans l'I/R: Effet protecteur d'H2S, PCa, et Dexa dans la modulation hémodynamique et ... (Omn.Pres.Franc.) (French Edition)

Sulfure d'hydrogène, Protéine C activée et Dexaméthasone dans l'I/R: Effet protecteur d'H2S, PCa, et Dexa dans la modulation hémodynamique et ... (Omn.Pres.Franc.) (French Edition)
by Khodr Issa (Author)

L’ischémie/reperfusion (I/R) est un phénomène très fréquent en clinique humaine. Ce phénomène est observé lors de la désobstruction d’une artère digestive, du traitement d’un état de choc, ainsi qu'au cours d'autres pathologies. L’interruption de la perfusion tissulaire (ischémie) et le rétablissement de celle-ci (reperfusion) sont la cause de la mise en place de troubles hémodynamiques et métaboliques. L’I/R est souvent présentée comme étant la principale source de l’hyperlactatémie et le moteur de la réponse inflammatoire lors des états de choc (cardiogénique, septique). Nous avons montré dans un modèle de choc hémorragique par I/R chez le rat que l'administration d'H2S limite la diminution de la pression artérielle moyenne et diminue le lactate...

© 2017